Rheumatoid Arthritis – Unmet Need – Unmet Need – TNFi-Refractory Rheumatoid Arthritis (US/EU)

Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s Orencia, Roche’s Actemra / RoActemra, Roche’s Rituxan / MabThera, AbbVie’s Rinvoq, Pfizer’s Xeljanz, Eli Lilly / Incyte’s Olumiant). Non-invasive targeted therapies such as JAK inhibitors offer more treatment options, but safety data on JAK inhibitors indicate a risk of serious infections, cardiovascular events, and/or malignancy, restricting these agents’ use in older patients with comorbidities. Although the RA therapy market offers multiple efficacious and relatively safe agents, patients refractory to TNF-alpha inhibitors have limited options; therefore, substantial unmet need remains in the treatment of TNF inhibitor-refractory RA. .

QUESTIONS ANSWERED

• What are the treatment drivers and goals for TNFi-refractory RA?
• Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key clinical and nonclinical attributes for TNF inhibitor-refractory RA?
• What are the prevailing areas of unmet need and opportunity in TNF inhibitor-refractory RA?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new TNF inhibitor-refractory RA drug?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

Key Analyses

• Importance of clinical and nonclinical product attributes to physicians
• Assessment of current drug performance againt treatment drivers and goals
• Physician perceptions of unmet needs in the indication and related indications
• Remaining drug development opportunities

Market covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European rheumatologists

Key drugs: Humira, Rituxan / MabThera, Orencia, Actemra / RoActemra, Xeljanz, Olumiant, Rinvoq